As the current Sudan Ebolavirus outbreak in the Republic of Uganda comes to a close, researchers are scrambling to conduct clinical trials to determine if a new set of vaccine candidates can match the efficacy found in previous Ebola vaccines.
An Original Article recently published in the peer-reviewed New England Journal of Medicine (NEJM) confirmed that two existing Ebola vaccines trigger durable immune responses, with antibodies detectable a year after the first dose administration.
New Ebola Vaccines Aspire to Achieve Older Version Success
Texas Testing Empowers Sudan Ebolavirus Vaccine and Therapeutic Development
While there are approved vaccines and therapies for one type of Ebola virus, a recent outbreak in Africa has highlighted the need for additional innovations.
Since the current Sudan ebolavirus (SUDV) outbreak began in September 2022, at least 142 people have been infected, and 55 people have died, including children and healthcare workers.
In Face of Tripledemic, CVS and Walgreens Limit Purchases of Pediatric Pain Meds
Medication limits are meant to ‘ensure equitable access,’ according to a CVS statement
Nursing Care Shortages Likely to Have Predated Pandemic
No evidence that large numbers of nurses left health care or hospital practice during first 18 months of pandemic
Coinfection With Flu, SARS-CoV-2 Described in Children
SARS-CoV-2 coinfection occurred in 6 percent of pediatric influenza-associated hospitalizations